Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome

被引：2
|
作者：
Cocorocchio, E. [1 ]
Nezi, L. [2 ]
Gandini, S. [2 ]
Manzo, T. [2 ]
Mazzarella, L. [2 ]
Lotti, F. [2 ]
Pala, L. [3 ]
Gnagnarella, P. [2 ]
Conforti, F. [3 ]
Pennacchioli, E. [4 ]
Fierro, M. T. [5 ]
Ribero, S. [6 ]
Senetta, R. [5 ]
Picciotto, F. [7 ]
Caliendo, V. [7 ]
Quaglino, P. [5 ]
Mazzarol, G. [3 ,8 ]
Orsolini, G. M. [4 ]
Prestianni, P. [4 ]
Ferrucci, P. F. [9 ]
机构：
[1] IRCCS, Ist Europeo Oncol, Hematoncol, Milan, Italy
[2] IRCCS, Ist Europeo Oncol, Experimental Oncol, Milan, Italy
[3] IRCCS, Ist Europeo Oncol, Med Oncol Melanoma Sarcoma & Rare Tumors, Milan, Italy
[4] IRCCS, Ist Europeo Oncol, Sarcoma & Rare Tumors, Surg Melanoma, Milan, Italy
[5] AOU Citta Salute & Sci Torino, Med Sci, Turin, Italy
[6] Azienda Osped Univ San Giovanni Battista Torino, Med Sci Dept, Turin, Italy
[7] AOU Citta Salute & Sci Torino Turin, Dermatol Surg, Turin, Italy
[8] IRCCS, Ist Europeo Oncol, Pathol & Lab Med, Milan, Italy
[9] IRCCS, Ist Europeo Oncol, Oncol Dept, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1457
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1072P
引用
收藏
页码：S889 / S890
页数：2
相关论文
共 50 条
  • [41] Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma
    Takahashi, Akira
    Namikawa, Kenjiro
    Ogata, Dai
    Jinnai, Shunichi
    Nakano, Eiji
    Yamazaki, Naoya
    JOURNAL OF DERMATOLOGY, 2023, 50 (04): : 525 - 535
  • [42] A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
    Postow, Michael A.
    Knox, Susan J.
    Goldman, Debra A.
    Elhanati, Yuval
    Mavinkurve, Vikram
    Wong, Phillip
    Halpenny, Darragh
    Reddy, Sunil K.
    Vado, Kenya
    McCabe, Danielle
    Ramirez, Kristen Aufiero
    Macri, Mary
    Schwarzenberger, Paul
    Ricciardi, Toni
    Ryan, Aileen
    Venhaus, Ralph
    Momtaz, Parisa
    Shoushtari, Alexander N.
    Callahan, Margaret K.
    Chapman, Paul B.
    Wolchok, Jedd D.
    Subrahmanyam, Priyanka B.
    Maecker, Holden T.
    Panageas, Katherine S.
    Barker, Christopher A.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 3193 - 3201
  • [43] VOLTAGE cohort D: Preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancer
    Takahashi, Y.
    Kato, T.
    Bando, H.
    Tsukada, Y.
    Inamori, K.
    Wakabayashi, M.
    Kumagai, S.
    Koyama, S.
    Kotani, D.
    Yuki, S.
    Komatsu, Y.
    Homma, S.
    Taketomi, A.
    Uemura, M.
    Fukui, M.
    Kojima, M.
    Sato, A.
    Nishikawa, H.
    Ito, M.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S77 - S77
  • [44] COST-EFFECTIVENESS OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA
    Tibet, B.
    VALUE IN HEALTH, 2018, 21 : S45 - S45
  • [45] COMPARISON OF HEALTHCARE COSTS IN FRANCE OF COMBINATION NIVOLUMAB AND IPILIMUMAB TREATMENT VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Bregman, B.
    Moshyk, A.
    Johnson, H. M.
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    VALUE IN HEALTH, 2020, 23 : S441 - S441
  • [46] Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
    Carlino, Matteo S.
    Long, Georgina V.
    CLINICAL CANCER RESEARCH, 2016, 22 (16) : 3992 - 3998
  • [47] Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal
    Wan, M. T.
    Ming, M. E.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (02) : 296 - 300
  • [48] A fatal primary gastric melanoma treated by a double immunotherapy with ipilimumab/nivolumab: description of a case report
    Longo, Raffaele
    Colin, Sebastien
    Streiff, Camille
    Wendel, Chloe
    Bonhomme, Axelle
    Sava, Claudia
    Campitiello, Marco
    Plastino, Francesca
    Egea, Julie
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (05) : 2615 - 2619
  • [49] Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
    Weber, J.
    Mandala, M.
    Del Vecchio, M.
    Gogas, H. J.
    Arance, A. M.
    Cowey, C. L.
    Dalle, S.
    Schenker, M.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Grob, J-J.
    Butler, M. O.
    Middleton, M. R.
    Maio, M.
    Atkinson, V.
    Queirolo, P.
    Gonzalez, R.
    Kudchadkar, R. R.
    Smylie, M.
    Meyer, N.
    Mortier, L.
    Atkins, M. B.
    Long, G. V.
    Bhatia, S.
    Lebbe, C.
    Rutkowski, P.
    Yokota, K.
    Yamazaki, N.
    Kim, T. M.
    de Pril, V.
    Sabater, J.
    Qureshi, A.
    Larkin, J.
    Ascierto, P. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1824 - 1835
  • [50] GASTROINTESTINAL EVENTS IN MELANOMA PATIENTS TREATED WITH IPILIMUMAB AND NIVOLUMAB
    Irwin, D.
    Davis, B. M.
    Bell, J.
    Galaznik, A.
    Garcia-Ribas, I
    VALUE IN HEALTH, 2018, 21 : S14 - S14
12345